A pair of data-driven quality improvement initiatives are helping Aetna improve care in two different areas. One involves improving oral hygiene to reduce infections; another helps reduce opioid-related deaths by contacting patients after an overdose.
Drug delivery platform will release medication for monthly dosing
August 30, 2019
Although lowering side effects plays an important role in oral contraceptive compliance, one of the biggest challenges for patients is adhering to the daily schedule of the pill. Forgetting one to three pills per cycle is a frequent problem among 15-51% of users, particularly among adolescents. Lyndra Therapeutics has received a $13 million grant from the Bill & Melinda Gates Foundation and is setting out to remove the daily pill compliance challenge. The company is in early development of a monthly oral contraceptive to provide women with a discreet, noninvasive, reversible contraception option.
In a randomized, controlled trial of adult patients with bone or joint infections, researchers found oral antibiotic therapy was noninferior to intravenous therapy based on treatment failure at one year.
Investigators evaluated 135 patients with Staphylococcus aureus bacteremia (SAB) in a prospective cohort study comparing early switch to oral linezolid to continued treatment with standard parenteral therapy (SPT). Patients with complicated SAB and osteoarticular infection were excluded. Early switch to oral therapy yielded similar outcomes to continued SPT and allowed earlier hospital discharge.
Deaths from ovarian cancer fell worldwide between 2002 and 2012 and are predicted to continue to decline through 2020 in the United States, European Union, and, to a lesser extent, in Japan, according to newly published research. The primary reason is the use of oral contraceptives and the long-term protection against ovarian cancer that they provide, say researchers.
In national statistics, the pill continues to lead the pack, with 25.9% of contracepting women (9.7 million women) reporting its use. Female sterilization was listed by 25.1% (9.4 million women), followed by the male condom (15.3%, 5.8 million women) and long-acting reversible contraception (11.6%, 4.4 million women).
Most participants in the Contraceptive Technology Update Contraception Survey say they support moving oral contraceptives over the counter. Almost 50% say they would support OTC availability of progestin-only pills, while 32% say they would support similar availability of combined hormonal pills.
Over the past several years, a small cadre of socially conservative policymakers and candidates, often hailing from swing states, have started to promote the idea of moving oral contraceptives over the counter as a supposed compromise in the political fight over contraception and, more broadly, reproductive health.